Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Chemo's muscle impact under the microscope in small breast cancer study

NCT ID NCT06536556

Knowledge-focused Sponsor: Institut de cancérologie Strasbourg Europe Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at how a single round of chemotherapy affects the muscles of women with early-stage breast cancer. Researchers compared three common chemo regimens: paclitaxel alone, paclitaxel plus trastuzumab, and paclitaxel plus carboplatin. They took muscle biopsies and measured strength, body composition, and quality of life before and four days after treatment. The study was terminated early and only enrolled 5 participants, so the findings are very limited.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
paclitaxel, trastuzumab, carboplatin
What this could lead to
If successful, this could help doctors understand how chemotherapy affects muscle health in breast cancer patients, potentially leading to better supportive care.
What could go wrong
The study was terminated early with only 5 participants, so results are very limited and may not be reliable. It was designed to observe short-term changes, not to test a new treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

5 people

The number who actually took part.

Started

May 2024

Finished

Feb 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with early-stage breast cancer receiving chemotherapy. It is planned to include a first group of 10 patients receiving their first administration of TAX and a second group of 10 patients receiving their first administration of TAX+TRASTU. A first session of assessments will take place before the first TAX or TAX+TRASTU session, and a second session 4 days (D4) after the session. It is planned to include the same number of patients per group, i.e. 10 patients per group, for a total of 20 patients in the study

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: TAX group : * Female ≥ 18 years * Stage I to III breast cancer * Patient who has not yet started treatment with TAX * Enrolled in a social security scheme * Able to speak, read and understand French TAX+TRASTU group : * Female ≥ 18 years of age * Stage I to III breast cancer * Patient who has not yet started treatment with TAX+TRASTU (Tolaney regimen) * Enrolled in a social security scheme * Able to speak, read and understand French Exclusion Criteria: * Prior exposure to chemotherapy * Musculoskeletal disorders, autoimmune, vascular or neuromuscular disease * Implantation of a pacemaker * Contraindications to fitness evaluation * Contraindication to local anesthesia for microbiopsy * Minor or protected adult * Pregnant women

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Breast cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Breast cancer

Contacts and locations

Locations

  • Institut de cancérologie Strasbourg europe

    Strasbourg, 67033, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.